Abstract
Myelofibrosis is a very debilitating chronic myeloproliferative neoplasm.1 It may be primary or develop late in the course of essential thrombocythemia or polycythemia vera, the two most common and benign myeloproliferative neoplasms. Patients with myelofibrosis have shortened survival and a reduced quality of life. The current treatment is palliative and aimed at alleviating symptoms due to splenomegaly, controlling myeloproliferation, and improving anemia and other cytopenias.In this issue of the Journal, Verstovsek et al. report on the results of a phase 1−2 trial of an oral Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) inhibitor, INCB018424, in advanced myelofibrosis. . . .
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
